Clinical review report : indication: treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapiesUstekinumab (Stelara/Stelara I.V.) Janssen Inc
This review aims to evaluate the beneficial and harmful effects of ustekinumab IV infusion (induction phase) and subcutaneous injection (maintenance phase) for the treatment of adult patients with moderately to severely active ulcerative colitis who have failed or were intolerant to treatment with immunomodulators or corticosteroids -- but never failed treatment with a biologic -- or have failed or were intolerant to treatment with a biologic..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
September 2020 |
|---|---|
| Erschienen: |
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health ; September 2020 |
| Ausgabe: |
Version: Final (with redactions). |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed August 3, 2021 ) |
|---|
| Umfang: |
1 online resource (1 PDF file (121 pages)) ; illustrations. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773182250 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773182250 | ||
| 003 | DE-627 | ||
| 005 | 20230428011903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773182250 | ||
| 035 | |a (DE-599)KEP06872148X | ||
| 035 | |a (NCBI)9917762973406676 | ||
| 035 | |a (EBP)06872148X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Clinical review report |b indication: treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapiesUstekinumab (Stelara/Stelara I.V.) Janssen Inc |
| 250 | |a Version: Final (with redactions). | ||
| 264 | 1 | |a Ottawa (ON) |b Canadian Agency for Drugs and Technologies in Health |c September 2020 | |
| 300 | |a 1 online resource (1 PDF file (121 pages)) |b illustrations. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed August 3, 2021 ) | ||
| 520 | |a This review aims to evaluate the beneficial and harmful effects of ustekinumab IV infusion (induction phase) and subcutaneous injection (maintenance phase) for the treatment of adult patients with moderately to severely active ulcerative colitis who have failed or were intolerant to treatment with immunomodulators or corticosteroids -- but never failed treatment with a biologic -- or have failed or were intolerant to treatment with a biologic. | ||
| 650 | 2 | |a Colitis, Ulcerative |x drug therapy |0 http://id.nlm.nih.gov/mesh/D003093Q000188 | |
| 650 | 2 | |a Ustekinumab |x therapeutic use |0 http://id.nlm.nih.gov/mesh/D000069549Q000627 | |
| 650 | 2 | |a Treatment Outcome |0 http://id.nlm.nih.gov/mesh/D016896 | |
| 651 | 2 | |a Canada |0 http://id.nlm.nih.gov/mesh/D002170 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK566849/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994079373 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994005620 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999781890 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995676456 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987671742 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987762845 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK566849/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK566849/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK566849/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK566849/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK566849/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||